#glp-1-agonists

#glp-1-agonists

Your pet dog or cat might soon be a chubby little munchkin no more. Welcome to the burgeoning era of - we swear we're not making this up - "ozempets," in which your servile critters might shed some extra pounds by taking animal-focused diabetes and weight loss drugs similar to Ozempic and Wegovy. It hasn't quite happened yet, but it's seemingly about to. As the New York Times reports, a San Francisco based biopharmaceutical firm called Okava Pharmaceuticals is expected to announce the first pilot study of using these drugs, which are known as GLP-1 agonists, on obese cats.

Live TV coverage of the event shows Novo Nordisk executive Gordon Findlay slumping to the floor inside the Oval Office, with several men nearby helping to guide his body safely to the ground. Medicare and Medicaid administrator Mehmet Oz grabbed Findlay under the shoulders to help him to the ground. Trump stands up from behind his desk in the Oval Office, but doesn't intervene. Health secretary Robert Kennedy Jr. can be seen walking briskly away from Findlay.

Novo Nordisk, creator of the mega-hit drug Ozempic, has seen a loss of nearly $100 billion in market value due to collapsing sales and missed forecasts.

In a small study, the drug liraglutide reduced monthly migraine episodes by nearly half among people with obesity who experience the headache-inducing condition.